Goldman Sachs Maintains Buy Rating for Cytek Biosciences: Here's What You Need To Know
Goldman Sachs has decided to maintain its Buy rating of Cytek Biosciences (NASDAQ:CTKB) and lower its price target from $14.00 to $12.00.
Shares of Cytek Biosciences are trading up 10.93% over the last 24 hours, at $8.22 per share.
A move to $12.00 would account for a 45.99% increase from the current share price.
About Cytek Biosciences
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells.
About Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.